Cefprozil

WikiDoc Resources for Cefprozil
Articles
Most recent articles on Cefprozil Most cited articles on Cefprozil Review articles on Cefprozil Articles on Cefprozil in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefprozil Images of Cefprozil Photos of Cefprozil Podcasts & MP3s on Cefprozil Videos on Cefprozil
Evidence Based Medicine
Cochrane Collaboration on Cefprozil Bandolier on Cefprozil TRIP on Cefprozil
Clinical Trials
Ongoing Trials on Cefprozil at Clinical Trials.gov Trial results on Cefprozil Clinical Trials on Cefprozil at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefprozil NICE Guidance on Cefprozil NHS PRODIGY Guidance FDA on Cefprozil CDC on Cefprozil
Books
Books on Cefprozil
News
Cefprozil in the news Be alerted to news on Cefprozil News trends on Cefprozil
Commentary
Blogs on Cefprozil
Definitions
Definitions of Cefprozil
Patient Resources / Community
Patient resources on Cefprozil Discussion groups on Cefprozil Patient Handouts on Cefprozil Directions to Hospitals Treating Cefprozil Risk calculators and risk factors for Cefprozil
Healthcare Provider Resources
Symptoms of Cefprozil Causes & Risk Factors for Cefprozil Diagnostic studies for Cefprozil Treatment of Cefprozil
Continuing Medical Education (CME)
CME Programs on Cefprozil
International
Cefprozil en Espanol Cefprozil en Francais
Business
Cefprozil in the Marketplace Patents on Cefprozil
Experimental / Informatics
List of terms related to Cefprozil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Synonyms: Cefprozilo [INN-Spanish], Cefprozil anhydrous, Cefprozilum [INN-Latin].

Brand Names: Arzimol, Brisoral, Cronocef, Procef, Serozil.

Dosing and Administration

Cefprozil tablets are administered orally.

Adults (13 years and older)

• Pharyngitis/Tonsillitis: 500 mg every 24h for 10 days.
• Acute sinusitis: 250 mg or 500 mg every 12h for 10 days.
• Secondary bacterial infection of acute bronchitis and acute bacterial exacerbation of chronic bronchitis: 500 mg every 12h for 10 days.
• Uncomplicated skin and skin structure infections: 250 mg every 12h for 10 days, 500 mg every 24h for 10 days, or 500 mg every 12h for 10 days.

Children (2 years-12 years)

• Pharyngitis/Tonsillitis: 7.5 mg/kg every 12h for 10 days.
• Uncomplicated skin and skin structure infections: 20 mg/kg every 24h for 10 days.

Infants & children (6 months-12 years)

• Otitis media: 15 mg/kg every 12h 10 days.
• Acute sinusitis: 7.5 mg/kg every 12h or 15 mg/kg every 12h for 10 days.

Renal impairment

• For patients with a creatinine clearance of 0-29 mL/min, administer 50% of the standard dosage in mg.

Hepatic impairment

• No dosage adjustment is necessary for patients with impaired hepatic function.

Adapted from the FDA Package Insert. Template:SIB